What is the prevalence of Chorea-acanthocytosis ChAc?

Chorea-acanthocytosis (ChAc) is an ultra-rare neurodegenerative disorder with an estimated prevalence of less than 1 in 1,000,000 people globally. While exact figures remain elusive due to frequent underdiagnosis, the condition is recognized as a rare form of neuroacanthocytosis affecting both males and females equally.

What is the estimated prevalence and incidence of Chorea-acanthocytosis?

Chorea-acanthocytosis is classified as an ultra-rare disease. Because it is often misdiagnosed as Huntington’s disease or other movement disorders, precise epidemiological data is limited. According to Orphanet, the prevalence is estimated at less than 1 per 1,000,000, and the annual incidence remains unknown. At DiseaseMaps.org, 6 members have identified with Chorea-acanthocytosis, reflecting the rarity of the condition and the value of patient-led registries in mapping these sparse global cases.

Does Chorea-acanthocytosis affect specific demographics?

Chorea-acanthocytosis does not show a clear predilection for any specific ethnic group or geographic region, and it affects males and females with equal frequency. The clinical presentation of Chorea-acanthocytosis typically follows these patterns:

• Age of onset: Most individuals experience initial symptoms between the ages of 20 and 40, though pediatric and late-adult onset cases have been documented.


• Inheritance: It is an autosomal recessive disorder caused by mutations in the VPS13A gene.


• Diagnostic hurdles: The presence of acanthocytes (spiky red blood cells) is a hallmark, but these are often transient or difficult to detect, leading to significant diagnostic delays.

Why is Chorea-acanthocytosis often underdiagnosed?

The rarity of Chorea-acanthocytosis makes it difficult for clinicians to recognize the condition during routine examinations. Patients with Chorea-acanthocytosis often present with complex movement disorders, such as orofacial dyskinesia and limb chorea, which overlap with more common conditions. The lack of standardized screening protocols for Chorea-acanthocytosis contributes to the significant gap between estimated prevalence and the number of confirmed cases.

Next steps

• Consult a neurologist specializing in movement disorders to discuss genetic testing for the VPS13A gene.


• Connect with the DiseaseMaps.org community to share experiences with other families living with Chorea-acanthocytosis.


• Review resources from the NIH GARD to stay updated on emerging clinical research and support services.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.

References

• Orphanet: Chorea-acanthocytosis (ORPHA:1820)


• NIH Genetic and Rare Diseases Information Center (GARD): Chorea-acanthocytosis


• OMIM (Online Mendelian Inheritance in Man): Chorea-acanthocytosis (#200150)


• National Institute of Neurological Disorders and Stroke (NINDS): Neuroacanthocytosis Information Page